ERBB2 and breast carcinoma: In breast cancer, HER2 overexpression, which is also the therapeutic target of approved inhibitors, can be activated by HER2 homodimerization and heterodimerization with other EGFR family members, and lead to the autophosphorylation of these tyrosine residues in intracellular domain to initiate a signal cascade.